<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZILEUTON</span><br/>(zi-leu'ton)<br/><span class="topboxtradename">Zyflo<br/></span><b>Classifications:</b> <span class="classification">bronchodilator (respiratory smooth muscle relaxant)</span>; <span class="classification">leukotriene receptor antagonist</span><br/><b>Prototype: </b>Zafirlukast<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>600 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits 5-lipoxygenase, the enzyme needed to start the conversion of arachidonic acid to leukotrienes. Leukotrienes are considered
         more important than prostaglandins as inflammatory agents; they induce bronchoconstriction and mucus production. Elevated
         sputum and blood levels of leukotrienes have been documented during acute asthma attacks.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Zileuton helps to prevent the signs and symptoms of asthma including airway edema, smooth muscle constriction, and altered
         cellular activity due to inflammation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis and chronic treatment of asthma in adults and children &gt;12 y.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to zileuton or zafirlukast, active liver disease, lactation, pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic insufficiency. Safety and effectiveness in children &gt;12 y are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Asthma</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> &gt;12 <i>y</i>, 600 mg q.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at meals and bedtime.</li>
<li>Store at room temperature, 15°30° C (59°86° F); protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Pain, asthenia, myalgia, arthralgia, fever, malaise, neck pain/rigidity. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, insomnia, nervousness, somnolence. <span class="typehead">CV:</span> Chest pain. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">dyspepsia,</span> nausea, constipation, flatulence, vomiting, elevated liver function tests, asymptomatic hepatitis. <span class="typehead">Skin:</span> Pruritus. <span class="typehead">Other:</span> Conjunctivitis, hypertonia, lymphadenopathy, vaginitis, UTI, leukopenia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May double <b>theophylline</b> levels and increase toxicity. Increases hypoprothrombinemic effects of <b>warfarin.</b> May increase levels of <span class="classification">beta blockers</span> (especially <b>propranolol</b>), leading to hypotension and bradycardia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Peak:</span> 1.7 h. <span class="typehead">Duration:</span> 58 h. <span class="typehead">Distribution:</span> 93% protein bound; secreted in the breast milk of rats. <span class="typehead">Metabolism:</span> Metabolized in liver primarily via glucuronide conjugation. <span class="typehead">Elimination:</span> Excreted primarily in urine (94%). <span class="typehead">Half-Life:</span> 2.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess respiratory status and airway function regularly.</li>
<li>Lab tests: Periodic CBC and routine blood chemistry; monthly liver function tests for 3 mo, then every 23 mo for rest
            of first year, then periodically.
         </li>
<li>Instructions for <small>CONCURRENT THERAPIES</small>: Reduce theophylline dose and closely monitor theophylline levels; closely monitor PT and INR with warfarin therapy; closely
            monitor phenytoin level with phenytoin therapy; closely monitor HR and BP for excessive beta blockade with propranolol therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take medication regularly even during symptom-free periods.</li>
<li>Drug is not intended to treat acute episodes of asthma.</li>
<li>Report to physician promptly S&amp;S of hepatic toxicity (see Appendix F) or flu-like symptoms. Follow-up lab work is very important.</li>
<li>Notify physician if condition worsens while using prescribed doses of all antiasthmatic medications.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>